Pyxis CEO Civik Thomas Receives Stock Option Award

What Happened Civik Thomas, CEO and Chairman of Pyxis Oncology (PYXS), was granted a derivative equity award on 2026-09-04 covering 2,503,050 shares. The Form 4 reports the acquisition as an award/derivative at $0.00 (no cash paid shown); a footnote identifies the grant as an option subject to a multi-year vesting schedule.

Key Details

• Transaction date: 2026-09-04; Form filed: 2026-09-08 (timely filing).
• Reported transaction type/code: A (award/grant of a derivative security).
• Shares/units granted: 2,503,050; reported price: $0.00; reported total value: $0.
• Vesting (footnote): 25% vests on the first anniversary of 9/4/2026; remaining 75% vests in 36 equal monthly installments thereafter, subject to continued employment.
• Shares owned after transaction: not specified in the provided filing excerpt.

Context This was a forward-looking equity award (an option subject to vesting), not an immediate open‑market purchase or sale. Such grants compensate and retain executives and only convert to controllable economic interest as they vest (and, if options, upon exercise). The filing appears timely; no sale or cash proceeds were reported in this transaction.